Aperio Group LLC increased its stake in shares of Zoetis Inc (NYSE:ZTS) by 7.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 251,188 shares of the company’s stock after buying an additional 16,412 shares during the quarter. Aperio Group LLC’s holdings in Zoetis were worth $18,096,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Wilbanks Smith & Thomas Asset Management LLC increased its holdings in Zoetis by 1.8% during the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock worth $354,000 after buying an additional 98 shares during the last quarter. Scotia Capital Inc. increased its holdings in Zoetis by 1.5% during the second quarter. Scotia Capital Inc. now owns 9,628 shares of the company’s stock worth $601,000 after buying an additional 142 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in Zoetis by 7.3% during the second quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock worth $368,000 after buying an additional 401 shares during the last quarter. Wendell David Associates Inc. increased its holdings in Zoetis by 8.4% during the fourth quarter. Wendell David Associates Inc. now owns 10,300 shares of the company’s stock worth $742,000 after buying an additional 800 shares during the last quarter. Finally, Bath Savings Trust Co increased its holdings in Zoetis by 18.7% during the third quarter. Bath Savings Trust Co now owns 5,308 shares of the company’s stock worth $338,000 after buying an additional 835 shares during the last quarter. Institutional investors and hedge funds own 93.73% of the company’s stock.
Several equities analysts have recently weighed in on ZTS shares. BMO Capital Markets reiterated a “hold” rating and issued a $65.00 target price on shares of Zoetis in a research note on Thursday, November 2nd. Cowen set a $80.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, November 17th. Morgan Stanley upgraded shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price for the company in a research note on Wednesday, November 29th. UBS Group reiterated a “neutral” rating on shares of Zoetis in a research note on Friday, November 24th. Finally, Citigroup upgraded shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price for the company in a research note on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company. Zoetis has a consensus rating of “Buy” and an average target price of $73.72.
Zoetis Inc (NYSE:ZTS) opened at $73.83 on Tuesday. The company has a market cap of $35,980.00, a P/E ratio of 38.86, a P/E/G ratio of 1.69 and a beta of 1.07. Zoetis Inc has a 12 month low of $52.00 and a 12 month high of $80.13. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be paid a dividend of $0.126 per share. The ex-dividend date is Thursday, January 18th. This represents a $0.50 annualized dividend and a yield of 0.68%. This is a boost from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s payout ratio is currently 26.32%.
COPYRIGHT VIOLATION WARNING: “Zoetis Inc (ZTS) Shares Bought by Aperio Group LLC” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thestockobserver.com/2018/02/06/zoetis-inc-zts-shares-bought-by-aperio-group-llc.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.